Diabetic ketoacidosis (DKA) is an acutely life-threatening complication of diabetes mellitus that occurs predominantly in type 1 diabetes, but is also increasingly occurring in people with type 2 diabetes. A special form is euglycemic DKA, which mainly occurs during therapy with SGLT2 inhibitors. Even though it has become rare and the mortality rate is now only just over 1%, these deaths are usually preventable. Timely diagnosis, standardized treatment protocols and, above all, prophylaxis are crucial for the prognosis.
Autoren
- Toralf Schwarz
Publikation
- CARDIOVASC
Related Topics
You May Also Like
- Actinic keratoses
Targeted Treatment of Multiple AK Lesions—Balancing Efficacy and Convenience
- Obesity: A Multimodal and Interdisciplinary Approach
New Swiss Clinical Practice Guideline Provides Guidance
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases
Pooled Expertise for Targeted Evaluation and Treatment
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa